Compositions and methods for treating lupus nephritis

JP2024511970A5Pending Publication Date: 2025-03-25GENENTECH INC +1
0 Cites 0 Cited by

Patent Information

Application Number
JP2023556725
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-16
Filing Date
2022-03-14
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

There are no approved treatments for lupus nephritis, particularly in adolescent patients, and current therapies have low complete response rates and are associated with toxicity, leading to poor long-term prognosis and increased risk of end-stage renal disease.

Method used

A method involving administration of a type II anti-CD20 antibody in multiple exposures, tailored by weight and time intervals, to deplete B cells effectively, combined with immunosuppressive agents like mycophenolate mofetil and glucocorticoids, to treat lupus nephritis.

Benefits of technology

The method achieves significant B cell depletion, reducing inflammation and improving renal response, potentially leading to complete renal response and better long-term prognosis for young patients with lupus nephritis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides methods for treating lupus nephritis in an individual aged 12 to under 18. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody.
Need to check novelty before this filing date? Find Prior Art